Business Context and Reporting Period
Company: Cartesian Therapeutics, Inc. (formerly Selecta Biosciences, Inc.)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended December 31, 2025
Business Overview: Cartesian is a late clinical-stage biotechnology company developing mRNA-based cell therapies for autoimmune diseases. The company's lead product candidate, Descartes-08, is an autologous CAR-T therapy targeting B-cell maturation antigen (BCMA). It is currently in Phase 3 development for Generalized Myasthenia Gravis (MG) and has expanded into Phase 2 development for myositis. The company operates with a wholly-owned manufacturing facility in Frederick, Maryland.
Key Financial Metrics
| Metric (in thousands) | 2025 | 2024 |
|---|---|---|
| Total Revenues | $2,797 | $38,913 |
| Net Loss | $(130,302) | $(77,424) |
| Operating Loss | $(143,405) | $(43,897) |
| Research & Development Expenses | $58,034 | $45,105 |
| General & Administrative Expenses | $31,468 | $30,126 |
| Impairment Charges | $56,700 | $7,579 |
| Cash, Cash Equivalents & Restricted Cash | $126,874 | $214,279 |
| Accumulated Deficit | $(822,373) | $(692,071) |
Liquidity: As of December 31, 2025, the company held approximately $126.9 million in cash and cash equivalents. Management believes this is sufficient to fund operations for at least the next 12 months.
Material Changes vs. Prior Period
- Revenue Decline: Total revenue decreased by 93% to $2.8 million from $38.9 million in 2024. This was primarily due to the recognition of a $30.0 million milestone payment from the Sobi License in 2024, which did not recur in 2025. Collaboration and license revenue dropped from $38.3 million to $0.4 million.
- Increased Net Loss: Net loss widened by 68% to $130.3 million, driven by higher operating expenses and a significant non-cash impairment charge.
- Impairment Charge: The company recorded a $56.7 million impairment charge related to the in-process research and development (IPR&D) asset for Descartes-08 in Systemic Lupus Erythematosus (SLE) following the decision to discontinue development in this indication.
- R&D Expense Growth: R&D expenses increased by 29% to $58.0 million, primarily due to costs associated with the Phase 3 AURORA trial for MG and increased headcount.
- Contingent Value Right (CVR) Liability: The fair value of the CVR liability decreased slightly to $392.1 million (from $395.5 million), resulting in a $4.4 million loss on change in fair value, compared to a $36.9 million loss in 2024.
Guidance, Outlook, and Risks
Management Commentary and Outlook
- Clinical Progress: The Phase 3 AURORA trial for Descartes-08 in MG is ongoing. The company initiated a Phase 2 trial for myositis in late 2025 and expects to commence it in the first half of 2026. Development of Descartes-08 for SLE has been paused and subsequently discontinued.
- Capital Needs: The company expects to continue incurring significant operating losses. While current cash reserves are projected to last 12 months, substantial additional funding will be required to complete clinical development and commercialization. Future financing may involve equity offerings, debt, or collaborations, which could be dilutive.
- Revenue Model: The company has no product revenue and does not expect to generate any for the foreseeable future. Revenue is currently derived from grants and collaboration agreements.
Risks and Contingencies
- Development Risk: Clinical drug development is inherently risky; failure in the Phase 3 AURORA trial would be material. The company has no approved products.
- Financial Risk: The company has an accumulated deficit of $822.4 million. Failure to raise additional capital could force the curtailment of operations.
- Regulatory Risk: The FDA is investigating risks of T-cell malignancy in BCMA-directed CAR-T therapies. While Cartesian's mRNA approach is distinct from DNA-based therapies, regulatory scrutiny remains a risk.
- Intellectual Property: The company relies on licensed technology from Biogen and the National Cancer Institute (NCI). Failure to maintain these licenses or protect IP could harm the business.
Key Facts for Investor Verification
- Cash Runway: Verify the sufficiency of the $126.9 million cash balance against the projected burn rate, given the 68% increase in net loss.
- Phase 3 AURORA Trial: Monitor enrollment rates and interim data for the pivotal MG trial, as this is the primary value driver.
- Discontinued SLE Program: Confirm the finality of the decision to abandon the SLE indication and the impact on the $56.7 million impairment charge.
- CVR Liability: Understand the mechanics of the Contingent Value Rights, which entitle holders to 100% of milestone and royalty proceeds from legacy assets (Sobi License), effectively limiting the company's ability to monetize those specific assets for its own operations.
- Manufacturing Capacity: Assess the scalability of the in-house Frederick, MD facility to support commercial volumes if approval is obtained.